These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

226 related items for PubMed ID: 16919303

  • 21. Evaluation of canine mast cell tumors for presence of estrogen receptors.
    Larsen AE, Grier RL.
    Am J Vet Res; 1989 Oct; 50(10):1779-80. PubMed ID: 2508516
    [Abstract] [Full Text] [Related]

  • 22. Clinicopathological features and outcome for dogs with mast cell tumors and bone marrow involvement.
    Marconato L, Bettini G, Giacoboni C, Romanelli G, Cesari A, Zatelli A, Zini E.
    J Vet Intern Med; 2008 Oct; 22(4):1001-7. PubMed ID: 18564225
    [Abstract] [Full Text] [Related]

  • 23. Cutaneous mast cell tumours in dogs.
    Kupfer J.
    Vet Rec; 2010 Mar 27; 166(13):407-8. PubMed ID: 20348476
    [No Abstract] [Full Text] [Related]

  • 24. Growth and metastasis of two canine mast cell tumors in SCID mice.
    Maruo K, Sugimoto T, Suzuki K, Shirota K, Yamane Y, Nomura T.
    J Vet Med Sci; 1996 Jun 27; 58(6):567-9. PubMed ID: 8811629
    [Abstract] [Full Text] [Related]

  • 25. Characterization of compound 584, an Abl kinase inhibitor with lasting effects.
    Puttini M, Redaelli S, Moretti L, Brussolo S, Gunby RH, Mologni L, Marchesi E, Cleris L, Donella-Deana A, Drueckes P, Sala E, Lucchini V, Kubbutat M, Formelli F, Zambon A, Scapozza L, Gambacorti-Passerini C.
    Haematologica; 2008 May 27; 93(5):653-61. PubMed ID: 18367480
    [Abstract] [Full Text] [Related]

  • 26. Advances in the diagnosis and management of cutaneous mast cell tumours in dogs.
    Dobson JM, Scase TJ.
    J Small Anim Pract; 2007 Aug 27; 48(8):424-31. PubMed ID: 17559522
    [Abstract] [Full Text] [Related]

  • 27. Expression of proto-oncogene C-kit and correlation with morphological evaluations in canine cutaneous mast cell tumors.
    Passantino L, Passantino G, Cianciotta A, Ribaud MR, Lo Presti G, Ranieri G, Perillo A.
    Immunopharmacol Immunotoxicol; 2008 Aug 27; 30(3):609-21. PubMed ID: 18608529
    [Abstract] [Full Text] [Related]

  • 28. AKT mediates the pro-survival effects of KIT in ovarian cancer cells and is a determinant of sensitivity to imatinib mesylate.
    Shaw TJ, Vanderhyden BC.
    Gynecol Oncol; 2007 Apr 27; 105(1):122-31. PubMed ID: 17169414
    [Abstract] [Full Text] [Related]

  • 29. Canine mast cell tumors express stem cell factor receptor.
    Reguera MJ, Rabanal RM, Puigdemont A, Ferrer L.
    Am J Dermatopathol; 2000 Feb 27; 22(1):49-54. PubMed ID: 10698217
    [Abstract] [Full Text] [Related]

  • 30. Evaluation of 12- and 24-month survival rates after treatment with masitinib in dogs with nonresectable mast cell tumors.
    Hahn KA, Legendre AM, Shaw NG, Phillips B, Ogilvie GK, Prescott DM, Atwater SW, Carreras JK, Lana SE, Ladue T, Rusk A, Kinet JP, Dubreuil P, Moussy A, Hermine O.
    Am J Vet Res; 2010 Nov 27; 71(11):1354-61. PubMed ID: 21034327
    [Abstract] [Full Text] [Related]

  • 31. Phosphorylated KIT as a predictor of outcome in canine mast cell tumours treated with toceranib phosphate or vinblastine.
    Thamm DH, Weishaar KM, Charles JB, Ehrhart EJ.
    Vet Comp Oncol; 2020 Jun 27; 18(2):169-175. PubMed ID: 31365175
    [Abstract] [Full Text] [Related]

  • 32. Multicenter prospective trial of hypofractionated radiation treatment, toceranib, and prednisone for measurable canine mast cell tumors.
    Carlsten KS, London CA, Haney S, Burnett R, Avery AC, Thamm DH.
    J Vet Intern Med; 2012 Jun 27; 26(1):135-41. PubMed ID: 22176473
    [Abstract] [Full Text] [Related]

  • 33. KIT oncogenic signaling mechanisms in imatinib-resistant gastrointestinal stromal tumor: PI3-kinase/AKT is a crucial survival pathway.
    Bauer S, Duensing A, Demetri GD, Fletcher JA.
    Oncogene; 2007 Nov 29; 26(54):7560-8. PubMed ID: 17546049
    [Abstract] [Full Text] [Related]

  • 34. C-kit inhibition by imatinib mesylate attenuates progenitor cell expansion and inhibits liver tumor formation in mice.
    Knight B, Tirnitz-Parker JE, Olynyk JK.
    Gastroenterology; 2008 Sep 29; 135(3):969-79, 979.e1. PubMed ID: 18602920
    [Abstract] [Full Text] [Related]

  • 35. Pathologic and molecular heterogeneity in imatinib-stable or imatinib-responsive gastrointestinal stromal tumors.
    Agaram NP, Besmer P, Wong GC, Guo T, Socci ND, Maki RG, DeSantis D, Brennan MF, Singer S, DeMatteo RP, Antonescu CR.
    Clin Cancer Res; 2007 Jan 01; 13(1):170-81. PubMed ID: 17200352
    [Abstract] [Full Text] [Related]

  • 36. Variation among pathologists in histologic grading of canine cutaneous mast cell tumors.
    Northrup NC, Harmon BG, Gieger TL, Brown CA, Carmichael KP, Garcia A, Latimer KS, Munday JS, Rakich PM, Richey LJ, Stedman NL, Cheng AL, Howerth EW.
    J Vet Diagn Invest; 2005 May 01; 17(3):245-8. PubMed ID: 15945380
    [Abstract] [Full Text] [Related]

  • 37. Imatinib-resistant K562 cells are more sensitive to celecoxib, a selective COX-2 inhibitor: role of COX-2 and MDR-1.
    Arunasree KM, Roy KR, Anilkumar K, Aparna A, Reddy GV, Reddanna P.
    Leuk Res; 2008 Jun 01; 32(6):855-64. PubMed ID: 18083230
    [Abstract] [Full Text] [Related]

  • 38. Sorafenib inhibits imatinib-resistant KIT and platelet-derived growth factor receptor beta gatekeeper mutants.
    Guida T, Anaganti S, Provitera L, Gedrich R, Sullivan E, Wilhelm SM, Santoro M, Carlomagno F.
    Clin Cancer Res; 2007 Jun 01; 13(11):3363-9. PubMed ID: 17545544
    [Abstract] [Full Text] [Related]

  • 39. Imatinib enhances human melanoma cell susceptibility to TRAIL-induced cell death: Relationship to Bcl-2 family and caspase activation.
    Hamaï A, Richon C, Meslin F, Faure F, Kauffmann A, Lecluse Y, Jalil A, Larue L, Avril MF, Chouaib S, Mehrpour M.
    Oncogene; 2006 Dec 07; 25(58):7618-34. PubMed ID: 16983347
    [Abstract] [Full Text] [Related]

  • 40. Expression of Ki67, BCL-2, and COX-2 in canine cutaneous mast cell tumors: association with grading and prognosis.
    Vascellari M, Giantin M, Capello K, Carminato A, Morello EM, Vercelli A, Granato A, Buracco P, Dacasto M, Mutinelli F.
    Vet Pathol; 2013 Jan 07; 50(1):110-21. PubMed ID: 22673539
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 12.